 malaria chloroquine proguanil chloroguanide nonimmune resident population endemic area high prevalence chloroquine resistance thirty nonimmune subjects Yaounde Cameroon prospective study efficacy safety weekly chloroquine daily proguanil chloroguanide Ch-P malaria prevention total Ch-P-treated subjects subjects prophylaxis Plasmodium falciparum infection period groups comparable demographic parameters degree exposure Clinical manifestations similar severities groups parasite counts subjects prophylaxis Side effects prophylaxis frequent minor weeks Prolonged administration Ch-P safe prevents falciparum malaria endemic area high prevalence chloroquine resistance